09/27/21 7:04 AMNasdaq : NRXP covid-19NRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)NRx Pharmaceuticals (Nasdaq: NRXP), a clinical stage, biopharmaceutical company, today announced top line data demonstrating improved outcomes at one year in highly comorbid patients with COVID-19 who were treated with ZYESAMI™."These latest data areRHEA-AIneutral
09/13/21 4:15 PMNYSE, Nasdaq : IQV, NRXP covid-19IQVIA and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 TreatmentIQVIA™, a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals. New medicines with new mechanisms of action are urgently needed, "said Robert Besthof, chief commercial officer and head of Operations of NRx.RHEA-AIpositive
09/08/21 7:48 AMNasdaq : NRXP conferencesNRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment ConferenceNRx Pharmaceuticals (NRx) (Nasdaq: NRXP) today announced that NRx's management team will present and host one-on-one investor meetings at the upcoming H.C. Wainwright Global Investment Conference September 13-15, 2021.Conference:H.C. Wainwright 23rdRHEA-AIneutral
08/26/21 6:48 AMNasdaq : NRXP NRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential TherapiesNRx Pharmaceuticals (NRx) (Nasdaq: NRXP) announced today it has signed an agreement with Cardinal Health to provide third party logistics and distribution of ZYESAMI™ upon the potential Emergency Use Authorization (EUA) approval by the US Food and DrugRHEA-AIpositive
08/24/21 6:48 AMNasdaq : NRXP NRx Pharmaceuticals Announces Closing of $30 Million Private PlacementNRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the investors in the private placement unregistered preferredRHEA-AIneutral
08/23/21 9:33 AMNasdaq : NRXP covid-19Participants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not NecessaryNRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, biopharmaceutical company noted today reports 1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authoritiesRHEA-AIneutral
08/19/21 9:18 AMNasdaq : NRXP NRx Pharmaceuticals Announces $30 Million Private PlacementNRx Pharmaceuticals (NRx) (Nasdaq: NRXP) (or the "Company"), a Delaware corporation, today announced that it has entered into definitive agreements with investors to purchase 2,727,273 shares of common stock in a private placement. The Company will alsoRHEA-AIneutral
08/18/21 11:53 AMNasdaq : NRXP covid-19NRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19NRx Pharmaceuticals (NRx) (NASDAQ: NRXP), a clinical stage, biopharmaceutical company today provided a safety update on ZYESAMI ™ (aviptadil) which is being tested in the ACTIV-3 Critical Care Phase 3 study sponsored by the National Institutes of Health.RHEA-AIneutral
08/16/21 9:32 PMNasdaq : NRXP NRx Pharmaceuticals Announces 2nd Quarter 2021 Financial UpdateNRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage biopharmaceutical company today provided a business update and financial results for the quarter ended June 30, 2021. NRx will host a conference call Tuesday, August 17, 2021, at 8:30AM EasternRHEA-AIneutral
08/11/21 4:20 PMNasdaq : NRXP conferencesNRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021NRx Pharmaceuticals (NRx) (Nasdaq: NRXP), a clinical stage, global biopharmaceutical company, today announced that management will report second quarter 2021 financial results after theRHEA-AIneutral